Imaging to understand whole-body processes such as novel drug interactions during therapeutic development will soon be accessible through Australia’s first research-dedicated Total Body PET (TB-PET).
The Sydney Imaging Core Research Facility at The University of Sydney, in partnership with Northern Sydney Local Health District (NSLHD) and the National Imaging Facility (NIF), is establishing a Total Body PET facility in the Department of Nuclear Medicine at Royal North Shore Hospital.
TB-PET can be used to capture molecular processes from all organs simultaneously. The high-performance instrument can be used to study diseases that affect the entire body and build a better picture of complex processes such as ageing, metabolism, brain signalling and drug interactions.
Due to its exquisite sensitivity, it also has the potential to use much lower radiation doses compared to conventional PET scanners, making it safe to scan children, healthy volunteers, and to scan patients repeatedly to better understand disease progression and treatment effects.
TB-PET is accessible for research studies through Sydney Imaging Core Research Facility, the University of Sydney Node of the National Imaging Facility. For more information, contact Dr Georgios Angelis.
To mark the launch of the Australian National Total Body PET, Australia’s first research-dedicated Total Body PET, The University of Sydney is hosting a webinar series.
Watch recordings and register for future webinars below.
Join us for an exciting exploration into the intricate networks of whole-body, multi-organ connectivity and discover how Total Body PET imaging technology is paving the way for unprecedented insights into human health and disease progression.
In this webinar Sydney Imaging partners with Sydney Infectious Diseases Institute to explore innovations in Total Body PET and its potential application in studies of the adaptive immune system. This new technology, enables all the tissues and organs of the body to be imaged simultaneously, including the kinetics of novel biomolecules, at exceptionally high sensitivity. This opens up exciting opportunities for exploring future clinical applications of PET in systemic conditions, including infectious diseases.
Prof Glaudemans discusses the differences between scanning on a Total Body PET compared to other conventional systems, highlights some key opportunities that Total Body PET systems may offer in the future.
Professor Michael Kassiou showcases the role of PET imaging in general, and Total Body PET in particular, in drug discovery. He discusses how Total Body PET can be used to identify novel targets for drug and radiopharmaceutical development and to assess their efficacy.
Dr Giancarlo Pascali provides an overview of the workflow for selecting the appropriate target, molecule, isotope, and experimental setup, highlighting the value of Total Body PET imaging.
Dr John Doan describes the current and future NIF plans for radiochemistry support for the Australian National Total Body PET Facility. He also discusses the infrastructure requirements to produce a range of radiotracers and discuss where they can be sourced from.
Introduction to the new facility, the operational model and the available resources to all researchers across Australia.
Overview of Total Body PET technology and how the new facility will fit within the existing clinical research imaging landscape.
Overview of the technical specifications and capabilities of the new Biograph Vision Quadra Total Body PET system set to be installed.